Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Blockade of neutral sphingomyelinase 2 exerts antitumor effect on metastatic castration resistant prostate cancer cells and promotes tumor regression when combined with Enzalutamide

American Journal of Cancer Research(2024)10.62347/xxxa3182Source: DataRank Database

Blockade of neutral sphingomyelinase 2 exerts antitumor effect on metastatic castration resistant prostate cancer cells and promotes tumor regression when combined with Enzalutamide is a research paper published in American Journal of Cancer Research (2024). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

Linked data & code

gen nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 0.19)OA: bronzeTopics (20)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (1)

Shams Ge Shams

Live enrichment

PubMed:39803655 PMC:PMC11711525 OpenAlex:https://openalex.org/W4405950927

NIGMS NIH HHS

Grant: P30 GM145498

National Institutes of Health

Grant: 3P30GM145498-02S1

Estrogenic Component of the Vascular Etiology of Alzheimer's Disease

FWCI

0.19

Citation Percentile

0.6%

Citation Trend

2025

bronze

journalhttps://doi.org/10.62347/xxxa3182

publisherhttps://doi.org/10.62347/xxxa3182

publisherhttps://e-century.us/files/ajcr/14/12/ajcr0161065.pdf

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39803655

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11711525

Fields of Study

Sphingolipid Metabolism and SignalingAutophagy in Disease and TherapyEndoplasmic Reticulum Stress and DiseaseMedicine03 medical and health sciences0302 clinical medicine

Keywords

EnzalutamideProstate cancerBlockadeCancer researchMedicineCancerInternal medicineOncologyReceptorAndrogen receptorMouse ModelMcrpcDptipN-Smase2

Sustainable Development Goals

SDG 0: Good health and well-being

Blockade of neutral sphingomyelinase 2 exerts antitumor effect on metastatic castration resistant prostate cancer cells and promotes tumor regression when combined with Enzalutamide

FAIR Checklist

Authors (1)

Funding (2 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)